67 / 69
67
90.
Branford S, Fletcher L, Cross NC, Müller MC, Hochhaus A, Kim DW,et al
. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood2008;112:3330-8.
91.
Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard
MA, et al. Trough imatinib plasma levels are associated
with both cytogenetic and molecular responses to
standard-dose imatinib in chronic myeloid leukemia.
Blood 2007;109:3496-9.
92.
Reinhold U, Hennig E, Leiblein S, Niederwieser D,
Deininger MW. FISH for BCR-ABL on interphases of
peripheral blood neutrophils but not of unselected white
cells correlates with bone marrow cytogenetics in CML
patients treated with imatinib. Leukemia 2003;17:1925-9.
93.
Mascarenhas CC, Cunha AF, Miranda EC, Zulli R, Silveira
RA, Costa FF, et al. New mutations detected by denaturing
high performance liquid chromatography during
screening of exon 6 bcr-abl mutations in patients with
chronic myeloid leukemia treated with tyrosine kinase
inhibitors. Leuk Lymphoma 2009;50:1148-54.
94.
Olavarria E, Ottmann OG, Deininger M, Clark RE, Bandini
G, Byrne J, et al. Response to imatinib in patients who
relapse after allogeneic stem cell transplantation for
chronic myeloid leukemia. Leukemia 2003;17:1707-12.
95.
Crawley C, Szydlo R, Lalancette M, Bacigalupo A, Lange
A, Brune M, et al. Outcomes of reduced-intensity
transplantation for chronic myeloid leukemia: an analysis
of prognostic factors from the Chronic Leukemia Working
Party of the EBMT. Blood 2005;106:2969-76.
96.
Lee SJ, Kukreja M, Wang T, Giralt SA, Szer J, Arora M, et
al. Impact of prior imatinib mesylate on the outcome of